Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 16;9:7504. doi: 10.1038/s41598-019-43668-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Tumor cell viability analysis via MTT assay. (a) Enhanced sensitivity of breast cancer phenotypes towards CRAd. Both breast cancer cell lines were treated with CRAd at different MOIs (1–64). Chemotherapy-resistant cells of both cell lines exhibited significantly high inhibition rates. (b) Sensitivity of breast cancer cells towards cisplatin. Both phenotypes of breast cancer cell lines showed a tremendous difference in response to variable concentrations of cisplatin. MCF-7/DDPR and M-231/DDPR exhibit very less sensitivity due to resistance. (c) Inhibitory effects of combined treatment with different cisplatin concentrations. High initial inhibition rate was achieved even at a lower dose of cisplatin, and a continuous increase in inhibition was seen with increasing cisplatin doses. The data shown are the average of triplicate experiments. Data are presented as the mean ± SD in A, B and C, (n = 3), *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.001 by two-tailed Student’s t test.